New Dermal Patch: Consistent High-Dose Administration Without Side Effects

A new ibuprofen skin patch now in development in the UK may provide clinicians with an alternative route of administration that eliminates the gastrointestinal complications associated with the oral form of this popular analgesic. Researchers at the University of Warwick, Coventry, working in conjunction with the Coventry-based bioadhesives company Medherant, report that their new transparent patch can deliver a consistent, high dose of ibuprofen spread over a 12-hour interval. The technology represents an improvement over currently available topical gels, in both ease of application and reduced risk of toxicity, due to the consistency and duration of dose administration.

The new Medherant patch uses a polymer technology licensed from Bostik (a global adhesives company), which can hold up to 30% of its weight in medication load. This represents a 5 to 10 times greater medication concentration than currently available patches and gels. It also has stronger adhesive properties, allowing it to remain stuck to the skin despite its heaver weight, but is still comfortable to remove. Nigel Davis, CEO of Medherant, stated that plans are in process to secure both FDA and EMEA approvals for the technology and to achieve global availability within the next 2 years.

Read other articles about patches, here.

Read more about the emerging technology here.



Related Content